Also known as glow blend, glow stack, ghk-cu/bpc-157/tb500, ghk + bpc + tb
Glow is a three-peptide research-chemical blend marketed primarily for skin, hair, and post-procedure recovery, combining GHK-Cu (a copper-binding tripeptide isolated by Loren Pickart in 1973), BPC-157 (a 15-residue synthetic peptide derived from a gastric-juice sequence), and TB-500 (a synthetic fragment closely related to thymosin beta-4). The blend's positioning derives from the regenerative reputations of the three components rather than from any direct study of the combination. Vendors supply Glow as both an injectable solution and as a compounded topical for skin and scalp application. No human pharmacology, efficacy, or safety data exist for the specific blend; all supportive evidence is component-level. The product is sold for research use only and is not approved by any regulatory authority for human therapeutic use; individual component evidence is summarized in their dedicated entries.
—
best
price
—
per
mg
—
vendors
tracked
Research-only
stage
Formulation note
GHK-Cu + BPC-157 + TB-500. Marketed for skin/hair healing.
What's in this blend
Skin
GHK-Cu is the copper(II) complex of the human tripeptide glycyl-L-histidyl-L-lysine (GHK), a naturally occurring fragment first isolated from human plasma in 1973 by Loren Pickart.
Recovery
BPC-157 (Body Protection Compound-157, also designated PL 14736 in the Pliva clinical program) is a synthetic 15-amino-acid pentadecapeptide originally derived from a putative cytoprotective fragment of human gastric juice protein.
Recovery
TB-500 is the research-chemical label most commonly applied to a synthetic peptide associated with the actin-binding region of thymosin beta-4 (Tbeta4).
Vendor data
Per-vendor pricing and verification tiers populate as the SavePeptides crawler comes online. Until then, browse all approved vendors directly.
Browse all vendorsMechanism of action
Glow has no mechanistic literature of its own; activity is inferred from the three components. GHK-Cu is a copper-binding tripeptide originally isolated from human plasma (Pickart 1973) that upregulates collagen, glycosaminoglycan, decorin, and elastin synthesis in dermal fibroblasts at picomolar-to-nanomolar concentrations, modulates matrix metalloproteinase activity, and has been shown by transcriptomic profiling to shift gene expression of more than 4,000 human genes toward a youthful pattern (Pickart & Margolina, 2018, PMC6073405; PMC4508379).
Pharmacokinetic properties
Half-life
Component-level: GHK-Cu has plasma t1/2 of a few hours but extended tissue retention via copper binding; BPC-157 ~minutes-hours in rodents; TB-500 ~2-3 h plasma in animal studies. No PK data exist for the blended product.
Routes
subcutaneous · topical
Bioavailability
Most often injected subcutaneously for systemic effects; also formulated topically for skin and scalp use, particularly leveraging the well-documented topical activity of GHK-Cu in cosmetic dermatology. Topical delivery of BPC-157 and TB-500 is not well characterized. No PK data on the blended product.
Amino-acid sequence
GHK-Cu: Gly-His-Lys (3 aa) complexed with Cu2+. BPC-157: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val (15 aa). TB-500: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Lys (synthetic TB-4 active-site fragment; vendor identity varies).
Use & research dosing
Research framing only. Community self-experimentation protocols typically dose roughly 200-500 mcg of each component subcutaneously per day, or a combined 1-2 mg per injection split across the three peptides, run in 4-8 week cycles followed by an off-period. Topical compounded formulations vary widely between compounders in per-component concentration and base vehicle. GHK-Cu has the broadest cosmetic-dermatology dosing precedent, typically 0.005-2% by weight in topical formulations, while BPC-157 and TB-500 lack any validated topical dose and their dermal penetration is poorly characterized. No human dose-finding study exists for the blended product. Vendors do not consistently disclose the per-component mass split in their vials, and independent assay verification is rare.
Research-use framing only. SavePeptides sells nothing for human consumption. Doses above reflect reported research / self-experimentation ranges, not clinical recommendations.
Glow is marketed in the peptide-vendor ecosystem as a skin-and-hair-focused derivative of "Wolverine," substituting GHK-Cu for the pure tissue-repair stack. As of May 2026 there are no human trials of the blend, no published PK, and no published safety data. The GHK-Cu component has the strongest individual evidence base, with decades of cosmetic-dermatology literature and routine inclusion in topical anti-aging products; the BPC-157 and TB-500 components remain preclinical-only for these indications. Per-component dosing in commercial Glow vials varies between compounders and is rarely independently verified. Buyers relying on Glow for skin or hair outcomes should be aware that the supportive evidence is almost entirely from GHK-Cu cosmetic studies plus extrapolation from preclinical work on the other two components.
— SavePeptides editorial desk · last updated 2026-05-25
Cautions & contraindications
Research foundation
Facts verified
2026-05-25
Confidence
low
What this means
Vendor data coming soon
001 — Independent
SavePeptides lists vendors after an initial review and distinguishes verified vendors where additional checks have been completed. We may earn commissions from referral links, and sponsored placements will be clearly disclosed.
002 — Vendor-funded
SavePeptides is free for buyers. We may earn a commission when you order through our links, but we do not lock deals behind a paywall, require an email to view codes, or inflate comparison prices.
003 — Research use
SavePeptides surfaces vendor, pricing, and coupon information for research compounds. These products are not intended, approved, or recommended for human consumption. Our content is informational only and does not constitute medical advice.